KAT2A and acute myeloid leukemia: Although KAT2A is not an essential gene for hematopoietic progenitor cells, targeting this gene represents a novel strategy for AML treatment, including the use of MB‐3 – a potent inhibitor of KAT2A for AML treatment.42